Hong Kong IPO Pipeline Swells to 410 Companies, Signaling Market Rebound

The Hong Kong IPO market is showing clear signs of recovery, with 410 companies currently preparing to list.

This surge is primarily driven by regulatory reforms like Chapters 18A and 18C, which facilitate listings for biotech and deep-tech firms, and a rise in companies pursuing dual listings in Hong Kong and mainland China.

With fundraising in the first quarter of 2026 hitting a five-year high, the market's capacity to absorb these new listings appears strong, supported by improved investor access and lower trading costs.

The Hong Kong stock exchange's IPO pipeline is currently filled with 410 companies, signaling a robust recovery in the market.

This resurgence isn't a random event; it's the direct result of strategic regulatory reforms. First, the exchange has actively expanded the pathways for companies to go public. The introduction of Chapter 18A in 2018 opened the door for pre-revenue biotech firms, and the more recent Chapter 18C in 2023 did the same for specialist technology companies, including those in AI and advanced manufacturing. These rules allow innovative but not-yet-profitable "hard tech" companies to access capital markets. Ongoing efforts, like the March 2026 "Competitiveness Review," aim to streamline the entire listing process, making it even more attractive for companies to apply.

Second, the market's capacity to absorb these new listings has grown. The investor pool has been widened through enhancements to the Stock Connect program, which now includes ETFs, allowing mainland Chinese investors easier access to Hong Kong stocks. Furthermore, a reduction in the stamp duty on stock trading in late 2023 lowered transaction costs, encouraging more active trading and improving liquidity for newly listed shares. These measures ensure that there is sufficient demand to meet the growing supply of IPOs.

Finally, the numbers confirm that this pipeline is not just a long list of applicants but a reflection of real market activity. In the first quarter of 2026, Hong Kong's IPO fundraising reached a five-year high, with deal volume and value surging compared to the previous year. This proves that the "funding window" is wide open and that companies in the pipeline are successfully converting their applications into closed deals. The strong performance validates the health of the market and boosts the confidence of other companies considering a Hong Kong listing.

Glossary -
A+H Dual Listing: A situation where a company is listed on both a mainland Chinese stock exchange (A-share) and the Hong Kong Stock Exchange (H-share), allowing it to access capital from both domestic and international investors.
Chapter 18A/18C: Listing rules introduced by the Hong Kong Stock Exchange to allow pre-revenue or pre-profit companies in specific innovative sectors, such as biotechnology (18A) and specialist technology (18C), to go public.

Hong Kong IPO Pipeline Swells to 410 Companies, Signaling Market Rebound

The Hong Kong IPO market is showing clear signs of recovery, with 410 companies currently preparing to list.

The Hong Kong stock exchange's IPO pipeline is currently filled with 410 companies, signaling a robust recovery in the market.

Glossary -
A+H Dual Listing: A situation where a company is listed on both a mainland Chinese stock exchange (A-share) and the Hong Kong Stock Exchange (H-share), allowing it to access capital from both domestic and international investors.
Chapter 18A/18C: Listing rules introduced by the Hong Kong Stock Exchange to allow pre-revenue or pre-profit companies in specific innovative sectors, such as biotechnology (18A) and specialist technology (18C), to go public.